Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for People With Prurigo Nodularis and Atopic Dermatitis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Galderma to Present New Data From Leading Aesthetics Portfolio and Launch* RESTYLANE EYELIGHT at AMWC 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Galderma Launches CETAPHIL Line for Sensitive Skin and New DAYLONG Sun Protection Product in Switzerland
quality dermatology line for sensitive skin is now available in Swiss pharmacies and drugstores
DAYLONG, a market-leading sun protection brand, is expanded to include practical DAYLONG Sun to Go cream and stick SPF 50+
Galderma has expanded its consumer care portfolio in Switzerland, where the global dermatology company originated and is headquartered. The expansion offers consumers more options for their dermatology needs. The move includes the introduction of the dermatologist-recommended CETAPHIL line for sensitive skin, as well as the expansion of the DAYLONG brand for sun protection.
Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
patients quality of life
1
The outcome of a post-hoc analysis of the phase 2b study published in the Journal of the European Academy of Dermatology and Venerology provides new possibilities for patients struggling with uncontrolled atopic dermatitis
Clinical trial subjects treated with nemolizumab demonstrated significant itch relief as early as 48 hours after treatment
that persisted throughout the duration of the study (up to week 16)
2
Subjects treated with nemolizumab reported significant sleep improvements as early as 72 hours after the first injection which were sustained, and improved further throughout the duration of the trial (up to week 16)